Swiss pharma company successfully completes inspections at three sites

CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and active pharmaceutical ingredient (API) manufacturing company, has successfully completed Swissmedic inspections at three of its sites, resulting in the renewal of GMP certificates.

The general surveillance audits were made at the Bubendorf, Aarau and Neuland sites earlier this year. No significant concerns were discovered during the inspections thereby allowing each site to have the GMP certification renewed.

“The successful inspections of the Bubendorf, Aarau and Neuland facilities reinforce our commitment to the highest quality standard in Switzerland and worldwide,” said Martin Schneider, chief quality officer at CARBOGEN AMCIS. “The three facilities meet all expectations related to cGMP and quality for API development and manufacturing services to support our customers. We are extremely pleased to continue our long-standing track record of successful inspections and regulatory audits.”

“Our company is continuously growing and expanding its operations, particularly at our facilities in Bubendorf, Aarau and Neuland. A positive audit is a critical component of our expansion process. We remain deeply committed to excellence, so quality is crucial to our success and our customer's satisfaction," said Mark Griffiths, CEO, Dishman Group.